Cubist Pharmaceuticals Inc (CBST.OQ)
64.80USD
1 Aug 2013
$2.47 (+3.96%)
$62.33
$62.46
$65.55
$62.46
382,176
329,145
$65.55
$38.54
About
Overall
| Beta: | 0.64 |
| Market Cap (Mil.): | $4,114.65 |
| Shares Outstanding (Mil.): | 66.01 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CBST.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 45.42 | 37.93 | 37.76 |
| EPS (TTM): | 1.37 | -- | -- |
| ROI: | 5.82 | 19.48 | 18.76 |
| ROE: | 10.23 | 20.17 | 19.59 |
Cubist to pay up to $1.6 billion for two antibiotics makers
- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.
UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers
* Cubist sees the sum of both deals to be accretive in 2015
Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion
- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln
(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)
U.S. court ruling favors Cubist in patent case versus Hospira
- A federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc .
U.S. court ruling favors Cubist in patent case vs Hospira
May 20 - A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc.
Cubist bid for Optimer before sale process began: sources
NEW YORK - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
Cubist bid almost $1 bln for Optimer before sale process-sources
NEW YORK, May 15 - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
Optimer shares rise after report names Glaxo, Cubist as potential buyers
- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker.
UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers
* Shares up 18 pct (Adds comments from an analyst, details)
Competitors
| Price | Change | |
|---|---|---|
| Shionogi & Co Ltd (4507.T) | ¥2,044 | +2.00 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
| Hospira, Inc. (HSP.N) | $42.03 | +1.33 |
| Forest Laboratories, Inc. (FRX.N) | $44.66 | +1.10 |
| Viropharma Inc (VPHM.OQ) | $32.00 | -2.32 |
| Theravance Inc (THRX.OQ) | $38.42 | -0.14 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

